Resource Summary Report

Generated by RRID on Sep 6, 2026

Capan-1

RRID:CVCL_0237
Type: Cell Line

Proper Citation

RRID:CVCL_0237

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0237

Proper Citation: RRID:CVCL_0237

Description: Cell line Capan-1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Pancreatic ductal adenocarcinoma

Defining Citation: PMID:327080, PMID:833871, PMID:1764370, PMID:3518877, PMID:6278935, PMID:6582512, PMID:6935474, PMID:7017212, PMID:7459858, PMID:8026879, PMID:8286197, PMID:8426738, PMID:8968085, PMID:9331070, PMID:10027410, PMID:10408907, PMID:11169957, PMID:11668190, PMID:12692724, PMID:14695172, PMID:15162061, PMID:15367885, PMID:16912165, PMID:18264088, PMID:18298655, PMID:18380791, PMID:20037478, PMID:20164919, PMID:20215515, PMID:20418756, PMID:21750719, PMID:22109279, PMID:22460905, PMID:25167228, PMID:25485619, PMID:25877200, PMID:26589293, PMID:27259358, PMID:27397505, PMID:28196595, PMID:29444439, PMID:30894373, PMID:30971826, PMID:31068700, PMID:31395879, PMID:35839778

Comments: Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: TCGA-110-CL cell line panel., Part of: NCI RAS program mutant KRAS cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Capan-1

Synonyms: CaPan-1, CAPAN-1, Capan 1, CAPAN 1, Capan1, CAPAN1

Cross References: BTO:BTO_0002744, CLO:CLO_0002197, EFO:EFO_0002153, MCCL:MCC:0000126, CLDB:cl639, CLDB:cl640, AddexBio:C0018001/31, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:HTB-79, BCRJ:0265, BioGRID_ORCS_Cell_line:844, BioSample:SAMN01821543, BioSample:SAMN01821620, BioSample:SAMN03471999, BioSample:SAMN05292467, BioSample:SAMN10987884, cancercelllines:CVCL_0237, CancerTools:161907, Cell_Model_Passport:SIDM00934, CGH-DB:162-1, CGH-DB:9269-4, ChEMBL-Cells:CHEMBL3307640, ChEMBL-Targets:CHEMBL614536, CLS:300143, Cosmic:724646, Cosmic:736270, Cosmic:753624, Cosmic:755302, Cosmic:808173, Cosmic:872997, Cosmic:913302, Cosmic:922252, Cosmic:923166, Cosmic:932516, Cosmic:933521, Cosmic:947395, Cosmic:948374, Cosmic:948726, Cosmic:949231, Cosmic:1006365, Cosmic:1090399, Cosmic:1108338, Cosmic:1122342, Cosmic:1198205, Cosmic:1299296, Cosmic:1320462, Cosmic:1534317, Cosmic:1571774, Cosmic:1761694, Cosmic:1995362, Cosmic:2434105, Cosmic-CLP:753624, DepMap:ACH-000354, DSMZ:ACC-244, DSMZCellDive:ACC-244, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:753624, GEO:GSM206452, GEO:GSM383933, GEO:GSM621902, GEO:GSM784706, GEO:GSM886920, GEO:GSM887986, GEO:GSM1024398, GEO:GSM1374438, GEO:GSM1374439, GEO:GSM1669663, IARC_TP53:1560, IGRhCellID:Capan1, IZSLER:BS TCL 9, KCLB:30079, LiGeA:CCLE_751, LINCS_LDP:LCL-1732, Lonza:1011, PharmacoDB:CAPAN1_184_2019, PRIDE:PXD003198, PRIDE:PXD030304, Progenetix:CVCL_0237, PubChem_Cell_line:CVCL_0237, SKY/M-FISH/CGH:1999, TOKU-E:773, Wikidata:Q54808589

ID: CVCL_0237

Record Creation Time: 20220427T215440+0000

Record Last Update: 20260905T174517+0000

Ratings and Alerts

No rating or validation information has been found for Capan-1.

No alerts have been found for Capan-1.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 396 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Safari M, et al. (2026) Combined HDAC and eIF4A inhibition: A novel epigenetic therapy for pancreatic ductal adenocarcinoma. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 84, 101312.

Jia A, et al. (2026) Dual targeting of SLC25A51 and succinate dehydrogenase selectively depletes mitochondrial NAD+ to eradicate KRAS-driven AML. Cell metabolism, 38(6), 1113.

Kopp A, et al. (2026) In Vivo Auto-tuning of Antibody-Drug Conjugate Delivery to Maximize Efficacy Using High-Avidity, Low-Affinity Antibodies. Molecular cancer therapeutics, 25(4), 610.

Yadav K, et al. (2026) Therapeutic targeting of GSK-3?? activation by the tyrosine kinase RYK in pancreatic ductal adenocarcinoma with BJ-2412, a novel sunitinib analogue. British journal of pharmacology, 183(15), 4196.

Yang J, et al. (2026) A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing an Immunotherapeutic Strategy for Pancreatic Ductal Adenocarcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(12), 2479.

Kaur T, et al. (2026) Loss of Regulator of G Protein Signaling 11 Promotes Protumorigenic Features in Pancreatic Cancer. Molecular cancer research : MCR, 24(1), 34.

Anh DXT, et al. (2026) GlycoChat Uncovers Glycan-Lectin Circuits in the Tumor Microenvironment of Pancreatic Cancer. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(14), e14735.

Kong C, et al. (2026) Targeting HAS2 to enhance anti-tumor immunity in pancreatic cancer via PD-L1 regulation. Communications biology, 9(1).

Takano K, et al. (2026) DS-3939a: A TA-MUC1-Directed Antibody-Drug Conjugate with Broad Antitumor Activity. Molecular cancer therapeutics, 25(1), 7.

Kwon YJ, et al. (2026) Basroparib inhibits YAP-driven cancers by stabilizing angiomotin. Molecular oncology, 20(5), 1284.

Shi M, et al. (2026) Transcriptomic landscape of transposable elements reveals LTR7-PLAAT4 as a potential oncogene and therapeutic target in pancreatic adenocarcinoma. Genome research, 36(2), 275.

Musiani D, et al. (2025) Uracil processing by SMUG1 in the absence of UNG triggers homologous recombination and selectively kills BRCA1/2-deficient tumors. Molecular cell, 85(6), 1072.

Chang TY, et al. (2025) Preclinical evaluation of a novel antibody-drug conjugate OBI-992 for Cancer therapy. Scientific reports, 15(1), 8735.

Tang J, et al. (2025) CD44 identified as a diagnostic biomarker for highly malignant CA19-9 negative pancreatic cancer. Cancer letters, 622, 217713.

Cerqua M, et al. (2025) The integrated stress response drives MET oncogene overexpression in cancers. The EMBO journal, 44(4), 1107.

Anastasio G, et al. (2025) Enhancing PDAC therapy: Decitabine-olaparib synergy targets KRAS-dependent tumors. iScience, 28(2), 111842.

Song L, et al. (2025) Dynamic control of RNA-DNA hybrid formation orchestrates DNA2 activation at stalled forks by RNAPII and DDX39A. Molecular cell, 85(3), 506.

Vandenbussche N, et al. (2025) EMT-associated bias in the Parsortix?? system observed with pancreatic cancer cell lines. Molecular oncology.

Kang HW, et al. (2025) SLC6A14-mediated glutamine promotes SYTL4-CXCL8 axis activation to drive gemcitabine resistance and immune evasion in pancreatic cancer. Experimental & molecular medicine, 57(12), 2943.

Zhang S, et al. (2025) Vitamin D Binding Protein, a Ligand of Integrin beta 1, Motivates Both Tumor Cells and Schwann Cells to Promote Perineural Invasion in Pancreatic Ductal Adenocarcinoma. Advanced science (Weinheim, Baden-Wurttemberg, Germany), e11726.